Key result
Dual antiplatelet therapy did not significantly reduce the 90-day risk of recurrent ischemic stroke compared to single antiplatelet therapy in patients presenting with acute stroke.
Why the study?
The study aimed to evaluate the comparative effectiveness of dual antiplatelet therapy versus single antiplatelet therapy in patients presenting with acute stroke at a tertiary care center.
Does dual antiplatelet therapy reduce the recurrence of ischemic stroke within 90 days compared to single antiplatelet therapy in adult patients with acute stroke (NIHSS ≤3)?
Population
250 patients aged 40-89 years with acute stroke at a tertiary care center in Muzaffarabad
Comparison
DAPT (n=129) vs SAPT (n=121)
Design
Retrospective observational cohort study
Follow-up
90 days
Authors
Loading...
Observational DAPT versus SAPT data in acute stroke should not change practice; leaves open need for randomized confirmation.
Cohort (n=250)
No
Does dual antiplatelet therapy reduce the recurrence of ischemic stroke within 90 days compared to single antiplatelet therapy in adult patients with acute stroke (NIHSS ≤3)?
p-value: p=0.312
In this retrospective cohort of patients with acute mild stroke, dual antiplatelet therapy was not significantly superior to single antiplatelet therapy for preventing 90-day stroke recurrence.
Aslam et al. (2025) conducted a cohort in acute stroke (n=250). Dual antiplatelet therapy vs. Single antiplatelet therapy was evaluated on recurrence of ischemic stroke within 90 days (p=0.312). Dual antiplatelet therapy did not significantly reduce the 90-day risk of recurrent ischemic stroke compared to single antiplatelet therapy in patients presenting with acute stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: